CD117在多发性骨髓瘤细胞中的表达及其意义

背景与目的:细胞表面分化抗原 CD117是酪氨酸激酶选择性抑制剂作用的靶点之一,细胞表面是否表达 CD117及表达的量与酪氨酸激酶选择性抑制剂作用关系密切.本研究探讨 CD117在各种多发性骨髓瘤( multiple myeloma,MM)细胞中的表达,为酪氨酸激酶选择性抑制剂在 MM中的应用提供理论依据,同时评价 CD117在 MM细胞中表达的意义.方法:采用 CD45/SSC双参数散点图设门方法进行三色流式细胞术测定细胞表面分化抗原 CD117、 CD56、 CD54.结果: 48例 MM患者中有 17例( 35.50%)瘤细胞 CD117表达阳性, 39例 (81 20% )CD56表达阳性, 48例 (100 00% )CD54表达阳性, 48例 MM患者瘤细胞 CD117阳性率低于 CD56、 CD54; CD117阳性率与骨髓中瘤细胞比例呈正相关; CD117在 IgG型的 MM中阳性率 (64.00% )高于其它如轻链型、 IgA型 MM; CD117阳性率在不同分期、初治或复发难治的 MM中差异无显著性 (P >0.05, P >0.01); CD117阳性的初治 MM患者对 VAD化疗方案的反应率 (71.43% )与 CD117阴性的反应率 (66.68% )比较无明显差异 (P >0.05).结论: CD117可作为 MM的肿瘤相关抗原, 也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志.

Expression of CD117 antigen on multiple myeloma and its significance

BACKGROUND & OBJECTIVE: Leukocyte differentiation antigen CD117 is one of the targets that tyrosine kinase selective inhibitors work on. Whether CD117 is expressed on the cell surface, and the expression level are highly correlated with tyrosine kinase selective inhibitors. This study was designed to investigate the expression of CD117 on multiple myeloma (MM) cells, which may provide a theoretical evidence for the use of tyrosine kinase selective inhibitors in MM,meanwhile,the importance of CD117 expression on MM cells was estimated. METHODS: CD117, CD56, and CD54 were measured by three-color flow cytometry with CD45/SSC gating strategy. RESULTS: Of 48 patients with MM, 17 (35.5%) had positive CD117 expression on myeloma cells, 39 (81.2%) had positive CD56 expression, and 48 (100.0%) had positive CD54 expression. CD117 expression on myeloma cells was lower than CD56, and CD54. CD117 positive expression was positive correlated with the percentage of myeloma cells in bone marrow. CD117 positive in IgG type of MM was 64%, higher than other types such as light chain or IgA. CD117 positivity showed no significant difference in different stages (P >0.05), and in patients haven't been pretreated, or relapsed after pretreated (P >0.01). In MM patients haven't been pretreated, the reaction rate of VAD chemotherapy in CD117 positive cases was 71.4%, and showed no significant difference (P >0.05) compared with the reaction rate of 66.7% in CD117 negative cases. CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.